Multi-layered control of PD-L1 expression in Epstein-Barr virus-associated gastric cancer

Abstract

Gastric cancer (GC) is the fifth most common cancer worldwide. In approximately 10% of GC cases, cancer cells show ubiquitous and monoclonal Epstein-Barr virus (EBV) infection. A significant feature of EBV-associated GC (EBVaGC) is high lymphocytic infiltration and high expression of immune checkpoint proteins, including programmed death-ligand 1 (PD-L1). This highlights EBVaGC as a strong candidate for immune checkpoint blockade therapy. Indeed, several recent studies have shown that EBV positivity in GC correlates with positive response to programmed cell death protein 1 (PD-1)/PD-L1 blockade therapy. Understanding the mechanisms that control PD-L1 expression in EBVaGC can indicate new predictive biomarkers for immunotherapy, as well as therapeutic targets for combination therapy. Various mechanisms have been implicated in PD-L1 expression regulation, including structural variations, post-transcriptional control, oncogenic activation of intrinsic signaling pathways, and increased sensitivity to extrinsic signals. This review provides the most recent updates on the multi-layered control of PD-L1 expression in EBVaGC.

Keywords

Epstein-Barr virus / gastric cancer / immunotherapy / programmed death-ligand 1

References

[1] Rawla P.Epidemiology of gastric cancer: global trends, risk factors and prevention..Prz Gastroenterol2019;14:26-38 PMCID:PMC6444111

[2] Street W.Cancer facts & figures 2019..1930;76

[3] Zali H,Azodi M.Gastric cancer: prevention, risk factors and treatment..Gastroenterol Hepatol Bed Bench2011;4:175-85 PMCID:PMC4017429

[4] Cancer Genome Atlas Research NetworkComprehensive molecular characterization of gastric adenocarcinoma..Nature2014;513:202-9 PMCID:PMC4170219

[5] Angell HK,Kim KM,Kim ST.PD-L1 and immune infiltrates are differentially expressed in distinct subgroups of gastric cancer..Oncoimmunology2019;8:e1544442 PMCID:PMC6351089

[6] Kim ST,Bass AJ,Odegaard JI.Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer..Nat Med2018;24:1449-58

[7] Rickinson A.Epstein-Barr virus..Virus Res2001;82:109-13

[8] Balfour HH Jr,Hogquist KA.Infectious mononucleosis..Clin Transl Immunol2015;4:e33 PMCID:PMC4346501

[9] Epstein M,Barr Y.Virus particles in cultured lymphoblasts from Burkitt’s lymphoma..Lancet1964;283:702-3

[10] Dalldorf G,Barnhart FE.An epidemiologic approach to the lymphomas of African children and Burkitt’s sacroma of the jaws..Perspect Biol Med1964;7:435-49

[11] Hsu JL.Epstein-Barr virus-associated malignancies: epidemiologic patterns and etiologic implications..Crit Rev Oncol Hematol2000;34:27-53

[12] Imai S,Sugiura M,Uemura Y.Gastric carcinoma: monoclonal epithelial malignant cells expressing Epstein-Barr virus latent infection protein..Proc Natl Acad Sci U S A1994;91:9131-5 PMCID:PMC44761

[13] Ribeiro J,Malta M,Silva F.Clinical and pathological characterization of Epstein-Barr virus-associated gastric carcinomas in Portugal..World J Gastroenterol2017;23:7292-302 PMCID:PMC5677199

[14] Oh ST,Moon UY,Shin DJ.A naturally derived gastric cancer cell line shows latency I Epstein-Barr virus infection closely resembling EBV-associated gastric cancer..Virology2004;320:330-6

[15] Nogueira C,Gradiz R,Caramelo F.Prevalence and characteristics of Epstein-Barr virus-associated gastric carcinomas in Portugal..Infect Agent Cancer2017;12:41 PMCID:PMC5518146

[16] Fukayama M,Iwasaki Y,Ooba T.Epstein-Barr virus-associated gastric carcinoma and Epstein-Barr virus infection of the stomach..Lab Invest1994;71:73-81

[17] Naseem M,Brezden-Masley C,Berger MD.Outlooks on Epstein-Barr virus associated gastric cancer..Cancer Treat Rev2018;66:15-22 PMCID:PMC5964025

[18] Derks S,Chiaravalli AM,Camargo MC.Abundant PD-L1 expression in Epstein-Barr Virus-infected gastric cancers..Oncotarget2016;7:32925-32 PMCID:PMC5078063

[19] Salmaninejad A,Shabgah AG,Alimardani M.PD-1/PD-L1 pathway: Basic biology and role in cancer immunotherapy..J Cell Physiol2019;234:16824-37

[20] Cao S,Wyczalkowski MA,Ley J.Dynamic host immune response in virus-associated cancers..Commun Biol2019;2:109 PMCID:PMC6430765

[21] Fuchs CS,Jang RW,Satoh T.Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 Trial..JAMA Oncol2018;4:e180013 PMCID:PMC5885175

[22] Fashoyin-Aje L,Chen H,Veeraraghavan J.FDA approval summary: pembrolizumab for recurrent locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma expressing PD-L1..Oncologist2019;24:103-9 PMCID:PMC6324629

[23] Ma LJ,Dong LQ,Duan M.Clinical significance of PD-1/PD-Ls gene amplification and overexpression in patients with hepatocellular carcinoma..Theranostics2018;8:5690-702 PMCID:PMC6276293

[24] Brar G.The role of pembrolizumab in the treatment of PD-L1 expressing gastric and gastroesophageal junction adenocarcinoma..Therap Adv Gastroenterol2019;12:1756284819869767 PMCID:PMC6724489

[25] Rimm DL,Taube JM,Bridge JA.A prospective, multi-institutional, pathologist-based assessment of 4 immunohistochemistry assays for PD-L1 expression in non-small cell lung cancer..JAMA Oncol2017;3:1051-8 PMCID:PMC5650234

[26] Cho J,Heo YJ,Kim NK.Four distinct immune microenvironment subtypes in gastric adenocarcinoma with special reference to microsatellite instability..ESMO Open2018;3:e000326 PMCID:PMC5890063

[27] Marcus L,Keegan P.FDA approval summary: pembrolizumab for the treatment of microsatellite instability-high solid tumors..Clin Cancer Res2019;25:3753-8

[28] Hislop AD,Gudgeon NH,Rickinson AB.Epitope-specific evolution of human CD8(+) T cell responses from primary to persistent phases of Epstein-Barr virus infection..J Exp Med2002;195:893-905 PMCID:PMC2193726

[29] Borozan I,Frappier L.Analysis of Epstein-Barr virus genomes and expression profiles in gastric adenocarcinoma..J Virol2018;92:e01239-17 PMCID:PMC5752941

[30] Song H,Im H,Kang GH.Interpretation of EBV infection in pan-cancer genome considering viral life cycle: LiEB (Life cycle of Epstein-Barr virus)..Sci Rep2019;9:3465 PMCID:PMC6401378

[31] Strong MJ,Coco J,Vinay DS.Differences in gastric carcinoma microenvironment stratify according to EBV infection intensity: implications for possible immune adjuvant therapy..PLoS Pathog2013;9:e1003341 PMCID:PMC3649992

[32] Camargo MC,Matsuo K,Liao LM.Circulating antibodies against Epstein-Barr virus (EBV) and p53 in EBV-positive and -negative gastric cancer..Cancer Epidemiol Biomarkers Prev2020;29:414-9

[33] Yi K.Patterns and mechanisms of structural variations in human cancer..Exp Mol Med2018;50:98 PMCID:PMC6082854

[34] Kataoka K,Sakata S,Couronné L.Frequent structural variations involving programmed death ligands in Epstein-Barr virus-associated lymphomas..Leukemia2019;33:1687-99 PMCID:PMC6755969

[35] Saito R,Kunita A,Seto Y.Overexpression and gene amplification of PD-L1 in cancer cells and PD-L1+ immune cells in Epstein-Barr virus-associated gastric cancer: the prognostic implications..Mod Pathol2017;30:427-39

[36] Wang Y,Manske MK,Sarangi V.Amplification of 9p24.1 in diffuse large B-cell lymphoma identifies a unique subset of cases that resemble primary mediastinal large B-cell lymphoma..Blood Cancer J2019;9:73 PMCID:PMC6717207

[37] Kataoka K,Takeda Y,Matsumoto M.Aberrant PD-L1 expression through 3’-UTR disruption in multiple cancers..Nature2016;534:402-6

[38] Xu M,Zhu Q,Yao YY.Genome-wide profiling of Epstein-Barr virus integration by targeted sequencing in Epstein-Barr virus associated malignancies..Theranostics2019;9:1115-24 PMCID:PMC6401403

[39] Mayr C.Regulation by 3’-untranslated regions..Annu Rev Genet2017;51:171-94

[40] Nomizo T,Tsuji T,Yasuda Y.Clinical impact of single nucleotide polymorphism in PD-L1 on response to nivolumab for advanced non-small-cell lung cancer patients..Sci Rep2017;7:45124 PMCID:PMC5362817

[41] Yeo MK,Seong IO,Kim JM.Association of PD-L1 expression and PD-L1 gene polymorphism with poor prognosis in lung adenocarcinoma and squamous cell carcinoma..Hum Pathol2017;68:103-11

[42] Lee SY,Choi JE,Hong MJ.Functional polymorphisms in PD-L1 gene are associated with the prognosis of patients with early stage non-small cell lung cancer..Gene2017;599:28-35

[43] Wu Y,Jia Z,Cao X.Polymorphism of the programmed death-ligand 1 gene is associated with its protein expression and prognosis in gastric cancer..J Gastroenterol Hepatol2019;34:1201-7

[44] Wang W,Li F,Gu Y.A frequent somatic mutation in CD274 3’-UTR leads to protein over-expression in gastric cancer by disrupting miR-570 binding..Hum Mutat2012;33:480-4

[45] Wang Q,Tang X,Guo L.The roles of microRNAs in regulating the expression of PD-1/PD-L1 immune checkpoint..Int J Mol Sci2017;18:2540 PMCID:PMC5751143

[46] Wang F,Zhang B,Wu Q.MicroRNA-19a/b regulates multidrug resistance in human gastric cancer cells by targeting PTEN..Biochem Biophys Res Commun2013;434:688-94

[47] Wang Y,Xie G,Zhao E.MicroRNA-152 regulates immune response via targeting B7-H1 in gastric carcinoma..Oncotarget2017;8:28125-34 PMCID:PMC5438636

[48] Chen L,Goswami S,Ahn YH.Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression..Nat Commun2014;5:5241 PMCID:PMC4212319

[49] Treece AL,Tang W,Morgan DR.Gastric adenocarcinoma microRNA profiles in fixed tissue and in plasma reveal cancer-associated and Epstein-Barr virus-related expression patterns..Lab Invest2016;96:661-71 PMCID:PMC5767475

[50] Alessandrini L,De Re V,Canzonieri V.Proposed molecular and miRNA classification of gastric cancer..Int J Mol Sci2018;19:1683 PMCID:PMC6032377

[51] Humphries B.The microRNA-200 family: small molecules with novel roles in cancer development, progression and therapy..Oncotarget2015;6:6472-98 PMCID:PMC4466628

[52] Marquitz AR,Chugh PE,Raab-Traub N.Expression profile of microRNAs in Epstein-Barr virus-infected AGS gastric carcinoma cells..J Virol2014;88:1389-93 PMCID:PMC3911632

[53] Shinozaki A,Ushiku T,Isogai M.Downregulation of microRNA-200 in EBV-associated gastric carcinoma..Cancer Res2010;70:4719-27

[54] Zhao J,Cheung KF,Lung RW.Genome-wide identification of Epstein-Barr virus-driven promoter methylation profiles of human genes in gastric cancer cells..Cancer2013;119:304-12

[55] Queen KJ,Zhang F,Scott RS.Epstein-Barr virus-induced epigenetic alterations following transient infection..Int J Cancer2013;132:2076-86 PMCID:PMC3578144

[56] Li Y,Tu S,Zhou Y.Epigenetically deregulated miR-200c is involved in a negative feedback loop with DNMT3a in gastric cancer cells..Oncol Rep2016;36:2108-16

[57] Anastasiadou E,Alimperti S,Pyzer AR.Epstein-Barr virus-encoded EBNA2 alters immune checkpoint PD-L1 expression by downregulating miR-34a in B-cell lymphomas..Leukemia2019;33:132-47 PMCID:PMC6327052

[58] Zhou Y,Lin YP.MiR-34a, as a suppressor, enhance the susceptibility of gastric cancer cell to luteolin by directly targeting HK1..Gene2018;644:56-65

[59] Kim SM,Hong SW.EBV-encoded EBNA1 regulates cell viability by modulating miR34a-NOX2-ROS signaling in gastric cancer cells..Biochem Biophys Res Commun2017;494:550-5

[60] Otsuka H,Funakami Y,Fujiwara T.Emerging evidence of translational control by AU-rich element-binding proteins..Front Genet2019;10:332 PMCID:PMC6507484

[61] Guo J,Shan T,Chen Y.Tristetraprolin overexpression in gastric cancer cells suppresses PD-L1 expression and inhibits tumor progression by enhancing antitumor immunity..Mol Cells2018;41:653-64 PMCID:PMC6078856

[62] Deng K,Shan T,Zhou H.Tristetraprolin inhibits gastric cancer progression through suppression of IL-33..Sci Rep2016;6:24505 PMCID:PMC4830935

[63] Sung WW,Chen PR,Lee JW.Positive regulation of HIF-1A expression by EBV oncoprotein LMP1 in nasopharyngeal carcinoma cells..Cancer Lett2016;382:21-31

[64] Wang M,Wu W,Ding H.Epstein-Barr virus-encoded microRNAs as regulators in host immune responses..Int J Biol Sci2018;14:565-76 PMCID:PMC5968849

[65] Hooykaas MJ,Wiertz EJ.Comprehensive profiling of functional Epstein-Barr virus miRNA expression in human cell lines..BMC Genomics2016;17:644 PMCID:PMC4987988

[66] Qiu J,Leahy L.The Epstein-Barr virus encoded BART miRNAs potentiate tumor growth in vivo..PLoS Pathog2015;11:e1004561 PMCID:PMC4295875

[67] Yang YC,Lambert PF.Dissecting the regulation of EBV’s BART miRNAs in carcinomas..Virology2017;505:148-54 PMCID:PMC5504693

[68] Zhang J,Zhou Y,Yu J.The oncogenic role of Epstein-Barr virus-encoded microRNAs in Epstein-Barr virus-associated gastric carcinoma..J Cell Mol Med2018;22:38-45 PMCID:PMC5742672

[69] Tsai CY,Liu KH,Chen TC.Comprehensive profiling of virus microRNAs of Epstein-Barr virus-associated gastric carcinoma: highlighting the interactions of ebv-Bart9 and host tumor cells..J Gastroenterol Hepatol2017;32:82-91

[70] Cristino AS,West RA,Law SC.EBV microRNA-BHRF1-2-5p targets the 3’UTR of immune checkpoint ligands PD-L1 and PD-L2..Blood2019;134:2261-70 PMCID:PMC6923667

[71] Skalsky RL,Gottwein E,Kang D.The viral and cellular microRNA targetome in lymphoblastoid cell lines..PLoS Pathog2012;8:e1002484 PMCID:PMC3266933

[72] Vlachos IS,Karagkouni D,Vergoulis T.DIANA-TarBase v7.0: indexing more than half a million experimentally supported miRNA:mRNA interactions..Nucleic Acids Res2015;43:D153-9 PMCID:PMC4383989

[73] Yoon CJ,Kim DH,Koo BK.Epstein-Barr virus-encoded miR-BART5-5p upregulates PD-L1 through PIAS3/pSTAT3 modulation, worsening clinical outcomes of PD-L1-positive gastric carcinomas..Gastric Cancer2020;epub ahead of print [PMID: 32206940 doi: 10.1007/s10120-020-01059-3]

[74] Cerezo M,Druillennec S,Malka-Mahieu H.Translational control of tumor immune escape via the eIF4F-STAT1-PD-L1 axis in melanoma..Nat Med2018;24:1877-86

[75] Jiang X,Giobbie-Hurder A,Hodi FS.The activation of MAPK in melanoma cells resistant to BRAF inhibition promotes PD-L1 expression that is reversible by MEK and PI3K inhibition..Clin Cancer Res2013;19:598-609

[76] Coelho MA,Rana S,Moore C.Oncogenic RAS signaling promotes tumor immunoresistance by stabilizing PD-L1 mRNA..Immunity2017;47:1083-99.e6 PMCID:PMC5746170

[77] Seo AN,Bae HI,Park KB.Exon 9 mutation of PIK3CA associated with poor survival in patients with Epstein-Barr virus-associated gastric cancer..Anticancer Res2019;39:2145-54

[78] Song M,Lu B,Zhang J.PTEN loss increases PD-L1 protein expression and affects the correlation between PD-L1 expression and clinical parameters in colorectal cancer..PLoS One2013;8:e65821 PMCID:PMC3681867

[79] Parsa AT,Panner A,Parney IF.Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma..Nat Med2007;13:84-8

[80] Kim YB,Bae WJ,Lee D.Functional loss of ARID1A is tightly associated with high PD-L1 expression in gastric cancer..Int J Cancer2019;145:916-26

[81] Menyhárt O,Győrffy B.Mutations defining patient cohorts with elevated PD-L1 expression in gastric cancer..Front Pharmacol2018;9:1522 PMCID:PMC6331584

[82] Mimura K,Okayama H,Kua LF.PD-L1 expression is mainly regulated by interferon gamma associated with JAK-STAT pathway in gastric cancer..Cancer Sci2018;109:43-53 PMCID:PMC5765310

[83] Zhang Y,Zhang W,Song Y.Constitutive activation of the canonical NF-κB signaling pathway in EBV-associated gastric carcinoma..Virology2019;532:1-10

[84] Shi Q,Liu W,Qi Y.Latent membrane protein 2A inhibits expression level of Smad2 through regulating miR-155-5p in EBV-associated gastric cancer cell lines..J Med Virol2020;92:96-106

[85] Iwakiri D,Samanta M.Epstein-Barr virus latent membrane protein 2A contributes to anoikis resistance through ERK activation..J Virol2013;87:8227-34 PMCID:PMC3700196

[86] Qi YF,Zhang Y,Xiao H.EBV down-regulates COX-2 expression via TRAF2 and ERK signal pathway in EBV-associated gastric cancer..Virus Res2019;272:197735

[87] Li H,Zhu FS,Pan CY.LPS promotes the expression of PD-L1 in gastric cancer cells through NF-κB activation..J Cell Biochem2018;119:9997-10004

[88] Wang X,Gao J,Dong B.Autophagy inhibition enhances PD-L1 expression in gastric cancer..J Exp Clin Cancer Res2019;38:140 PMCID:PMC6440013

[89] Xu D,Li RY,Xiao C.PD-L1 Expression is regulated by NF-κB during EMT signaling in gastric carcinoma..Onco Targets Ther2019;12:10099-105 PMCID:PMC6883928

[90] Hino R,Murakami N,Shinozaki A.Activation of DNA methyltransferase 1 by EBV latent membrane protein 2A leads to promoter hypermethylation of PTEN gene in gastric carcinoma..Cancer Res2009;69:2766-74

[91] Cai L,Jiang Q,Lyu X.Epstein-Barr virus-encoded microRNA BART1 induces tumour metastasis by regulating PTEN-dependent pathways in nasopharyngeal carcinoma..Nat Commun2015;6:7353 PMCID:PMC4507016

[92] Cai LM,Luo WR,Ye YF.EBV-miR-BART7-3p promotes the EMT and metastasis of nasopharyngeal carcinoma cells by suppressing the tumor suppressor PTEN..Oncogene2015;34:2156-66

[93] Moon JW,Kim BS,Lim H.IFNγ induces PD-L1 overexpression by JAK2/STAT1/IRF-1 signaling in EBV-positive gastric carcinoma..Sci Rep2017;7:17810 PMCID:PMC5736657

[94] Kawazoe A,Kuboki Y,Nagatsuma AK.Clinicopathological features of programmed death ligand 1 expression with tumor-infiltrating lymphocyte, mismatch repair, and Epstein-Barr virus status in a large cohort of gastric cancer patients..Gastric Cancer2017;20:407-15

[95] Li Z,Sun L,Liu R.PD-L1 expression is associated with massive lymphocyte infiltration and histology in gastric cancer..Hum Pathol2016;55:182-9

[96] Thompson ED,Murphy A,Cuka N.Patterns of PD-L1 expression and CD8 T cell infiltration in gastric adenocarcinomas and associated immune stroma..Gut2017;66:794-801 PMCID:PMC4958028

[97] Wallach D,Malinin NL,Kovalenko AV.Tumor necrosis factor receptor and Fas signaling mechanisms..Annu Rev Immunol1999;17:331-67

[98] Billiau A.Interferon-γ: biology and role in pathogenesis. Advances in Immunology Volume 62.1996;Elsevier61-130

[99] Jiang X,Deng X,Ge J.Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape..Mol Cancer2019;18:10 PMCID:PMC6332843

[100] Iwai Y,Tanaka Y,Honjo T.Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade..Proc Natl Acad Sci U S A2002;99:12293-7 PMCID:PMC129438

[101] Lee SJ,Lee SW,Suh SI.Interferon regulatory factor-1 is prerequisite to the constitutive expression and IFN-gamma-induced upregulation of B7-H1 (CD274)..FEBS Lett2006;580:755-62

[102] Bellucci R,Bommarito D,Hansen SH.Interferon-γ-induced activation of JAK1 and JAK2 suppresses tumor cell susceptibility to NK cells through upregulation of PD-L1 expression..Oncoimmunology2015;4:e1008824 PMCID:PMC4485824

[103] Ohtani H,Takegawa S,Yoshie O.Abundant expression of CXCL9 (MIG) by stromal cells that include dendritic cells and accumulation of CXCR3+ T cells in lymphocyte-rich gastric carcinoma..J Pathol2009;217:21-31

[104] Sasaki S,Sakai K,Yoshiyama H.EBV-associated gastric cancer evades T-cell immunity by PD-1/PD-L1 interactions..Gastric Cancer2019;22:486-96

[105] Fang W,Hong S,Chen N.EBV-driven LMP1 and IFN-γ up-regulate PD-L1 in nasopharyngeal carcinoma: Implications for oncotargeted therapy..Oncotarget2014;5:12189-202 PMCID:PMC4322961

[106] Su S,Chen F,Du J.CRISPR-Cas9-mediated disruption of PD-1 on human T cells for adoptive cellular therapies of EBV positive gastric cancer..OncoImmunology2016;6:e1249558 PMCID:PMC5283615

[107] Nakayama A,Kunita A,Kanda T.Viral loads correlate with upregulation of PD-L1 and worse patient prognosis in Epstein-Barr Virus-associated gastric carcinoma..PLoS One2019;14:e0211358 PMCID:PMC6350976

[108] Iwakiri D,Samanta M,Ebihara T.Epstein-Barr virus (EBV)-encoded small RNA is released from EBV-infected cells and activates signaling from Toll-like receptor 3..J Exp Med2009;206:2091-9 PMCID:PMC2757889

[109] Lemery S,Pazdur R.First FDA approval agnostic of cancer site - when a biomarker defines the indication..N Engl J Med2017;377:1409-12